RIVAC-INC.
7.8.2019 11:02:06 CEST | Business Wire | Press release
RIVAC Inc. has announced the release of an iPhone App 'FrontShot' that enables real-time display and shooting of a straight frontal view of any plane, even if the camera is pointed from an oblique direction. Operation is simple, and you can see a straight frontal view of any plane, such as a document or wall, through the camera.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005001/en/
Official website: https://www.english.rivac.co.jp
[Background of FrontShot development]
There are times when you want to shoot a straight frontal view of an object such as a document, wall, poster, or time-table. In cases like this, it is convenient if you can just point your camera from an oblique direction, and see the straight frontal view. FrontShot was developed to make this possible. Even if you point your camera from an oblique direction, any sort of plane —documents, walls, etc.— can be viewed as a straight frontal image.
[Features]
Has three modes: horizontal plane, vertical plane, and slanted plane.
- Can handle any plane
The app can handle not only horizontal and vertical planes, but also slanted planes, and thus it is possible to see a straight frontal view of any plane. Naturally, it is also possible to see straight frontal views of ceilings. (Ceilings are regarded as horizontal planes.)
- Simple operation
Operation is extremely simple. For a horizontal plane, no special operation is necessary. Simply point the camera, and the straight frontal image will appear. For a vertical or slanted plane, the orientation of the plane must be designated (automatically or manually), but if the mode is set to automatic, a straight frontal image will appear just by pointing the camera, as with a horizontal plane. Operation is simple in manual mode too. Just point the camera in the direction of the plane, and press the button. A straight frontal image of the plane will appear.
*In the automated mode for vertical and slanted planes, the system calculates the direction of the plane by recognizing the horizontal and vertical lines which appear.
- Display in real-time
Processing is performed at high speed using our unique technology, and this makes it possible to display straight frontal images in real-time.
[Uses]
The app can be used for a variety purposes including: documents, posters, whiteboards, time-tables, buildings, signs, pictures, lettering and pictures drawn on the ground, and online sale items (clothes, books, CDs, other flat items).
[App information]
App name |
: |
FrontShot |
Device |
: |
iPhone (iOS9 or later) |
Category |
: |
Photo & Video |
Price |
: |
Check at the App Store. (A free trial is available. The product version can be purchased from the free version via in-app purchase.) |
| Released | : | August 5, 2019 |
iTunes URL |
: |
|
Official website |
: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom